Related Experiment Video
Updated: Mar 13, 2026
Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
Published on: February 3, 2026
Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach
James J Farrell1, Jennifer Moughan, Jonathan L Wong
1From the *Yale Center for Pancreatic Disease, Yale School of Medicine, New Haven, CT; †Statistics and Data Management Center, NRG Oncology, Philadelphia, PA; ‡Department of Medicine, John A Burns School of Medicine, University of Hawaii, Honolulu, HI; §Department of Radiation Oncology, University of Maryland, Baltimore, MD; ∥Oncology Program, Toledo Clinic, Toledo, OH; ¶Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL; #Saint Vincent Comprehensive Cancer Center, New York; and **The Oncology Consortia of Criterium Inc, Saratoga Springs, NY; ††California Cancer Institute, Temple City, CA; ‡‡Graduate Institute of Medical Sciences, College of Medicine, and §§Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan; ∥∥Department of Pathology, Cross Cancer Center, University of Alberta, Edmonton, Alberta, Canada; ¶¶Department of Pathology, H. Lee Moffitt Cancer Center, Tampa, FL; ##Karmanos Cancer Institute; and ***Department of Oncology and Cancer Biology Graduate Program, Wayne State University, Detroit, MI; †††Department of Radiation Oncology, Montifiore Medical Center, Bronx, NY; and ‡‡‡Department of Radiation Oncology, The Canberra Hospital, Australian National University, Canberra, Australia.
Researchers identified RRM2 as a potential predictive marker for gemcitabine response in pancreatic cancer, alongside human equilibrative nucleoside transporter 1. Other biomarkers like DCK, RRM1, and p53R2 showed no predictive value in this study.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Research
Background:
- Pancreatic cancer treatment often involves gemcitabine, but predicting patient response remains challenging.
- Validated predictive markers are crucial for guiding precision medicine in pancreatic cancer.
- Previous studies suggested human equilibrative nucleoside transporter 1 (hENT1) as a predictive marker, but the role of gemcitabine metabolism pathway biomarkers is debated.
Purpose of the Study:
- To investigate the predictive value of gemcitabine metabolism pathway biomarkers (DCK, RRM1, RRM2, p53R2) in pancreatic cancer patients.
- To correlate protein expression of these biomarkers with treatment outcomes (overall survival and disease-free survival) in patients receiving gemcitabine or 5-fluorouracil.
- To further evaluate potential predictive markers for gemcitabine response in pancreatic cancer.
Main Methods:
- Analysis of tumor DCK, RRM1, RRM2, and p53R protein expression using tissue microarray and immunohistochemistry.
- Correlation of biomarker expression with overall survival and disease-free survival in 229 eligible patients from the Radiation Therapy Oncology Group 9704 trial.
- Unconditional logistic regression analysis was employed to assess the association between biomarkers and treatment outcomes.
Main Results:
- RRM2 protein expression was significantly associated with survival in the gemcitabine treatment arm.
- No significant association was found between DCK, RRM1, or p53R2 protein expression and survival in the gemcitabine arm.
- The study analyzed data from 229 patients randomized to either 5-fluorouracil or gemcitabine.
Conclusions:
- The findings do not support the predictive value of DCK, RRM1, or p53R2 for gemcitabine response in pancreatic cancer.
- Human equilibrative nucleoside transporter 1 (hENT1) and potentially RRM2 should be prioritized as predictive markers for gemcitabine treatment response.
- Further research should focus on validating hENT1 and RRM2 for personalized treatment strategies in pancreatic cancer.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...